Evidence map›Paper›PMID 29562258›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

A Competing-Risk Approach for Modeling Length of Stay in Severe Malaria Patients in South-East Asia and the Implications for Planning of Hospital Services.

Claire M Keene, Arjen Dondorp, Jane Crawley, Eric O Ohuma, Mavuto Mukaka

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Lab efficiency and improvements in the management of bloodstream infections: a before and after study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Economic evaluation of severe malaria in children under 14 years in Zambia.Cost effectiveness and resource allocation : C/E · 2022
    Article
  9. Article
  10. Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  11. Article
  12. Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Claire M KeeneCentre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom.
Arjen DondorpCentre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom.
Jane CrawleyCentre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom.
Eric O OhumaCentre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom.
Mavuto MukakaCentre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom.
Medawar Building for Pathogen Research · GBMahidol Oxford Tropical Medicine Research Unit · THUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Management of severe malaria with limited resources requires comprehensive planning. Expected length of stay (LOS) and the factors influencing it are useful in the planning and optimisation of service delivery. Methods: A secondary, competing-risk approach to survival analysis was performed for 1217 adult severe malaria patients from the South-East Asia Quinine Artesunate Malaria Trial. Results: Twenty percent of patients died; 95.4% within 7 days compared to 70.3% of those who were discharged. Median time to discharge was 6 days. Compared to quinine, artesunate increased discharge incidence (subdistribution-Hazard ratio, 1.24; [95% confidence interval 1.09-1.40]; P = .001) and decreased incidence of death (0.60; [0.46-0.80]; P < .001). Low Glasgow coma scale (discharge, 1.08 [1.06-1.11], P < .001; death, 0.85 [0.82-0.89], P < .001), high blood urea-nitrogen (discharge, 0.99 [0.99-0.995], P < .001; death, 1.00 [1.00-1.01], P = .012), acidotic base-excess (discharge, 1.05 [1.03-1.06], P < .001; death, 0.90 [0.88-0.93], P < .001), and development of shock (discharge, 0.25 [0.13-0.47], P < .001; death, 2.14 [1.46-3.12], P < .001), or coma (discharge, 0.46 [0.32-0.65], P < .001; death, 2.30 [1.58-3.36], P < .001) decreased cumulative incidence of discharge and increased incidence of death. Conventional Kaplan-Meier survival analysis overestimated cumulative incidence compared to competing-risk model. Conclusions: Clinical factors on admission and during hospitalisation influence LOS in severe malaria, presenting targets to improve health and service efficiency. Artesunate has the potential to increase LOS, which should be accounted for when planning services. In-hospital death is a competing risk for discharge; an important consideration in LOS models to reduce overestimation of risk and misrepresentation of associations.

Indexed as

AdultAntimalarialsArtesunateAsia, SoutheasternFemaleHumansLength of StayMalariaMaleQuinineRetrospective StudiesYoung AdultAntimalarialsArtesunateQuinine

Identifiers

PMID29562258
PMCPMC6137114
OpenAlexW2790161816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.